REFERENCES
- Deutsch E. Disseminated intravascular coagulation in prostatic disease. Prog Clin Biol Res 1976; 6: 313–27.
- Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Cancer 1992; 70: 656–8.
- Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulop-athy in patients with neoplasms: clinical, pathophysio-logic and therapeutic features. Medicine 1977; 56: 1–37.
- Matzkin H, Braf Z. Paraneoplastic syndromes associated with prostatic carcinoma. J Urol 1987; 138: 1129–33.
- Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 1995; 55: 4881–5.
- Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. Ann Rev Med 1979; 30: 359–74.
- Pellman CM, Ridlon HC, Phillips LL. Manifestation and management of hypofibrinogenemia and fibrinolysis in patients with carcinoma of the prostate. J Urol 1966; 96: 375–9.
- Samaha RJ, Bruns TNC, Ross GJ. Chronic intravascular coagulation in metastatic prostate cancer. Arch Surg 1973; 106: 295–8.
- Goldenberg SL, Fenster HN, Perler Z, McLoughlin MG. Disseminated intravascular coagulation in carcinoma of prostate: role of estrogen therapy. Urology 1983; 22: 130–2.
- Adamson AS, Francis JL, Witherow RO, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl 1993; 75: 100–4.
- Alving BM, Abeloff MD, Bell W. Spontaneous remis-sion of recurring disseminated intravascular coagulation associated with prostatic carcinoma. Cancer 1976; 37: 928–30.
- Pergament ML, Swaim WR, Blackard CE. Disseminated intravascular coagulation in the urologic patient. J Urol 1976; 116: 1–7.
- Al-Mondhiry H, Manni A, Owen J, Gordon R. Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. Am J Hematol 1988; 28: 141–5.
- Burgess NA, Hudd C, Rees RWM. Haemostatic pitfalls in advanced prostatic cancer. Br J Urol 1993; 71: 231–3.
- Zacharski LR, Wojtukiewicz MZ, Constantini V, Ornstein DL, Memoli VA. Pathways of coagulation/ fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104–16.
- Drewinko B, Giacco G, Cobb P, Trujillo JM, Guinee V, von Eschenbach A. Untreated prostatic carcinoma is not associated with frequent thrombohemorrhagic disorders. Urology 1987; 30: 11–7.